Johnson & Johnson (NYSE:JNJ) Shares Sold by Shelton Capital Management

Shelton Capital Management reduced its stake in shares of Johnson & Johnson (NYSE:JNJFree Report) by 10.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 95,146 shares of the company’s stock after selling 10,900 shares during the period. Shelton Capital Management’s holdings in Johnson & Johnson were worth $14,819,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Capital Square LLC grew its stake in shares of Johnson & Johnson by 1.4% during the 2nd quarter. Capital Square LLC now owns 4,245 shares of the company’s stock worth $703,000 after acquiring an additional 58 shares during the period. RPG Investment Advisory LLC boosted its stake in Johnson & Johnson by 1.2% in the 2nd quarter. RPG Investment Advisory LLC now owns 4,876 shares of the company’s stock worth $807,000 after purchasing an additional 60 shares during the period. Texas Capital Bancshares Inc. TX boosted its stake in Johnson & Johnson by 1.1% in the 2nd quarter. Texas Capital Bancshares Inc. TX now owns 5,744 shares of the company’s stock worth $951,000 after purchasing an additional 61 shares during the period. FIDELIS iM LLC boosted its stake in Johnson & Johnson by 3.1% in the 4th quarter. FIDELIS iM LLC now owns 2,117 shares of the company’s stock worth $374,000 after purchasing an additional 64 shares during the period. Finally, TFG Advisers LLC boosted its stake in Johnson & Johnson by 0.4% in the 3rd quarter. TFG Advisers LLC now owns 18,330 shares of the company’s stock worth $2,855,000 after purchasing an additional 67 shares during the period. 68.40% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have weighed in on JNJ. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Wells Fargo & Company cut Johnson & Johnson from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $170.00 to $163.00 in a research note on Wednesday, December 13th. Morgan Stanley decreased their price target on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 24th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $181.00 price target on shares of Johnson & Johnson in a research note on Wednesday. Finally, UBS Group raised Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $167.00 to $180.00 in a research note on Friday, December 1st. Seven analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $177.31.

Get Our Latest Stock Analysis on JNJ

Johnson & Johnson Stock Up 0.6 %

Shares of JNJ stock traded up $0.93 during mid-day trading on Friday, hitting $162.31. The company’s stock had a trading volume of 3,612,448 shares, compared to its average volume of 7,142,741. Johnson & Johnson has a 52-week low of $144.95 and a 52-week high of $175.97. The business has a 50-day moving average price of $159.06 and a 200 day moving average price of $157.68. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.91 and a current ratio of 1.16. The stock has a market cap of $390.97 billion, a price-to-earnings ratio of 11.77, a PEG ratio of 2.71 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJGet Free Report) last posted its quarterly earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share for the quarter, topping the consensus estimate of $2.28 by $0.01. The firm had revenue of $21.40 billion during the quarter, compared to analysts’ expectations of $21.02 billion. Johnson & Johnson had a return on equity of 37.27% and a net margin of 37.79%. The company’s revenue was down 9.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.35 earnings per share. Research analysts predict that Johnson & Johnson will post 10.65 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 5th. Investors of record on Tuesday, February 20th will be given a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a yield of 2.93%. The ex-dividend date is Friday, February 16th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 34.47%.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the sale, the executive vice president now owns 141,416 shares in the company, valued at $22,099,078.32. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.20% of the stock is owned by company insiders.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.